tetano
Editor, Senior Moderator
Gut. 2020 Apr 17. pii: gutjnl-2020-321244. doi: 10.1136/gutjnl-2020-321244. [Epub ahead of print]
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
Kennedy NA[SUP]1,[/SUP][SUP]2[/SUP], Jones GR[SUP]3,[/SUP][SUP]4[/SUP], Lamb CA[SUP]5,[/SUP][SUP]6[/SUP], Appleby R[SUP]7[/SUP], Arnott I[SUP]4[/SUP], Beattie RM[SUP]8[/SUP], Bloom S[SUP]9[/SUP], Brooks AJ[SUP]10[/SUP], Cooney R[SUP]11,[/SUP][SUP]12[/SUP], Dart RJ[SUP]13,[/SUP][SUP]14[/SUP], Edwards C[SUP]15[/SUP], Fraser A[SUP]16[/SUP], Gaya DR[SUP]17,[/SUP][SUP]18[/SUP], Ghosh S[SUP]11,[/SUP][SUP]12[/SUP], Greveson K[SUP]14[/SUP], Hansen R[SUP]18,[/SUP][SUP]19[/SUP], Hart A[SUP]20,[/SUP][SUP]21[/SUP], Hawthorne AB[SUP]22[/SUP], Hayee B[SUP]13,[/SUP][SUP]23[/SUP], Limdi JK[SUP]24,[/SUP][SUP]25[/SUP], Murray CD[SUP]14[/SUP], Parkes GC[SUP]26,[/SUP][SUP]27[/SUP], Parkes M[SUP]28[/SUP], Patel K[SUP]29[/SUP], Pollok RC[SUP]29,[/SUP][SUP]30[/SUP], Powell N[SUP]21,[/SUP][SUP]31[/SUP], Probert CS[SUP]32,[/SUP][SUP]33[/SUP], Raine T[SUP]28[/SUP], Sebastian S[SUP]34[/SUP], Selinger C[SUP]35[/SUP], Smith PJ[SUP]32[/SUP], Stansfield C[SUP]36[/SUP], Younge L[SUP]37[/SUP], Lindsay JO[SUP]26,[/SUP][SUP]27[/SUP], Irving PM[SUP]13,[/SUP][SUP]38[/SUP], Lees CW[SUP]39,[/SUP][SUP]4[/SUP].
Author information
Abstract
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
? Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
KEYWORDS:
crohn's colitis; crohn's disease; ulcerative colitis
PMID:32303607DOI:10.1136/gutjnl-2020-321244
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic.
Kennedy NA[SUP]1,[/SUP][SUP]2[/SUP], Jones GR[SUP]3,[/SUP][SUP]4[/SUP], Lamb CA[SUP]5,[/SUP][SUP]6[/SUP], Appleby R[SUP]7[/SUP], Arnott I[SUP]4[/SUP], Beattie RM[SUP]8[/SUP], Bloom S[SUP]9[/SUP], Brooks AJ[SUP]10[/SUP], Cooney R[SUP]11,[/SUP][SUP]12[/SUP], Dart RJ[SUP]13,[/SUP][SUP]14[/SUP], Edwards C[SUP]15[/SUP], Fraser A[SUP]16[/SUP], Gaya DR[SUP]17,[/SUP][SUP]18[/SUP], Ghosh S[SUP]11,[/SUP][SUP]12[/SUP], Greveson K[SUP]14[/SUP], Hansen R[SUP]18,[/SUP][SUP]19[/SUP], Hart A[SUP]20,[/SUP][SUP]21[/SUP], Hawthorne AB[SUP]22[/SUP], Hayee B[SUP]13,[/SUP][SUP]23[/SUP], Limdi JK[SUP]24,[/SUP][SUP]25[/SUP], Murray CD[SUP]14[/SUP], Parkes GC[SUP]26,[/SUP][SUP]27[/SUP], Parkes M[SUP]28[/SUP], Patel K[SUP]29[/SUP], Pollok RC[SUP]29,[/SUP][SUP]30[/SUP], Powell N[SUP]21,[/SUP][SUP]31[/SUP], Probert CS[SUP]32,[/SUP][SUP]33[/SUP], Raine T[SUP]28[/SUP], Sebastian S[SUP]34[/SUP], Selinger C[SUP]35[/SUP], Smith PJ[SUP]32[/SUP], Stansfield C[SUP]36[/SUP], Younge L[SUP]37[/SUP], Lindsay JO[SUP]26,[/SUP][SUP]27[/SUP], Irving PM[SUP]13,[/SUP][SUP]38[/SUP], Lees CW[SUP]39,[/SUP][SUP]4[/SUP].
Author information
Abstract
The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government's advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.
? Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
KEYWORDS:
crohn's colitis; crohn's disease; ulcerative colitis
PMID:32303607DOI:10.1136/gutjnl-2020-321244